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q spinal muscular atrophy (SMA) is a common auto-
somal recessive disorder in humans and the leading
genetic cause of infantile death. Patients lack a func-
 
tional survival of motor neurons (
 
SMN1
 
) gene, but carry
one or more copies of the highly homologous 
 
SMN2
 
 gene.
A homozygous knockout of the single murine 
 
Smn
 
 gene is
embryonic lethal. Here we report that in the absence of the
 
SMN2
 
 gene, a mutant SMN A2G transgene is unable to
rescue the embryonic lethality. In its presence, the A2G
transgene delays the onset of motor neuron loss, resulting
in mice with mild SMA. We suggest that only in the presence
5
 
of low levels of full-length SMN is the A2G transgene able
to form partially functional higher order SMN complexes
 
essential for its functions. Mild SMA mice exhibit mo-
tor neuron degeneration, muscle atrophy, and abnormal
EMGs. Animals homozygous for the mutant transgene are
less severely affected than heterozygotes. This demonstrates
the importance of SMN levels in SMA even if the protein is
expressed from a mutant allele. Our mild SMA mice will
be useful in (a) determining the effect of missense mutations
in vivo and in motor neurons and (b) testing potential
therapies in SMA.
 
Introduction
 
Proximal spinal muscular atrophy (SMA)* is a common
autosomal recessive neurodegenerative disease in humans
characterized by loss of the spinal motor neurons and atrophy
of the limb and trunk muscles (Crawford and Pardo, 1996;
Melki, 1997). It occurs with a frequency of 1 in 10,000
individuals and is the most common genetic cause of infant
mortality (Roberts et al., 1970). Based on the age at onset
and severity of the disease phenotype, the proximal SMAs
have been classified into type I (severe), type II (intermediate),
and type III (mild) SMA (Munsat and Davies, 1992). All
three forms of the disease are due to loss or mutation of the
telomeric survival of motor neurons gene (
 
SMN1
 
) (Bussaglia
et al., 1995; Lefebvre et al., 1995; Parsons et al., 1996; Hahnen
et al., 1997; Talbot et al., 1997). Mutations in an almost
identical copy gene, 
 
SMN2
 
, do not cause disease. The critical
difference between the two genes is a C to T transition in
exon 7 of 
 
SMN2
 
, which affects splicing of this exon (Lorson
et al., 1999; Monani et al., 1999a). Thus, 
 
SMN1 
 
produces a
majority of the full-length SMN transcript, whereas 
 
SMN2
 
generates mostly an isoform lacking exon 7. The protein
product of the 
 
 
 
7 transcript is thought to be unstable and
rapidly degraded (Lorson and Androphy, 2000). SMA patients
who lack 
 
SMN1
 
 but carry a varying number of copies of
 
SMN2
 
 presumably produce insufficient full-length SMN
protein for motor neuron survival. The disease phenotype is
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modulated by 
 
SMN2
 
 copy number, likely due to the low
levels of full-length SMN produced by 
 
SMN2
 
 (Campbell et
al., 1997; McAndrew et al., 1997).
The 38-kD SMN protein is ubiquitously expressed (Coo-
vert et al., 1997; Lefebvre et al., 1997), often localizing in
dot-like structures termed gems. Gems overlap with, or are
in close proximity to, coiled bodies (Liu and Dreyfuss, 1996;
Young et al., 2000). SMN is thought to be important in sn-
RNP biogenesis and mRNA splicing (Pellizzoni et al.,
1998), but is most likely a multifunctional molecule (Fischer
et al., 1997; Liu et al., 1997; Buhler et al., 1999; Strasswim-
mer et al., 1999; Charroux et al., 1999; Campbell et al.,
2000; Gangwani et al., 2001; Jones et al., 2001; Pellizzoni et
al., 2001a,b; Terns and Terns, 2001; Young et al., 2001).
However, it is not clear which of SMN’s functions is critical
specifically to motor neurons.
In keeping with its housekeeping functions, an 
 
Smn
 
knockout in mice is embryonic lethal (Schrank et al., 1997).
To create a viable animal model of SMA, the 
 
SMN2
 
 gene was
introduced into 
 
Smn
 
 
 
/
 
 
 
 mice (Hsieh-Li et al., 2000; Monani
et al., 2000). One to two–copy 
 
SMN2;Smn
 
 
 
/
 
 
 
 mice exhibit a
type I SMA phenotype. 8–16 copies of 
 
SMN2
 
 completely
ameliorate the disease phenotype. Inducing 
 
SMN2
 
 to pro-
duce higher levels of SMN protein therefore seems an attrac-
tive option in treating SMA. A number of groups have re-
ported molecules capable of inducing 
 
SMN2
 
 to produce
higher levels of SMN (Baron-Delage et al., 2000; Andreassi
et al., 2001; Chang et al., 2001; Zhang et al., 2001). It is es-
sential that these be tested in appropriate animal models be-
fore human clinical trials are undertaken. Although the ex-
isting animal models have been extremely important in
furthering the understanding of the pathophysiology of the
SMA disease process, it is clear that a more suitable animal
model is needed to address the next generation of in vivo ex-
periments. In this study, we show that an SMN A2G mis-
sense mutation rescues the severe SMA phenotype in low
copy 
 
SMN2;Smn
 
 
 
/
 
 
 
 mice but is unable to rescue 
 
Smn
 
 
 
/
 
 
 
 em-
bryonic lethality in the absence of the 
 
SMN2
 
 gene. Increased
SMN protein in 
 
SMN A2G;SMN2;Smn
 
 
 
/
 
 
 
 
 
mice affects the
timing of motor neuron loss and results in animals with a
mild SMA phenotype. Mild SMA mice exhibit muscle atro-
phy, motor neuron degeneration, and abnormal electromyo-
graphs (EMGs). These characteristics, in particular the elec-
trophysiology, serve as easily assayed outcome measures in
therapeutic strategies in SMA. Importantly, we also show
that SMN A2G is unable to efficiently self-associate, a prop-
erty required for the formation of “active” SMN complexes.
We suggest that mutant oligomers are unstable and fail to
bind components that are essential for one or more of SMN’s
functions. This results in a rapid turnover of the protein, un-
derlining the importance of some, albeit low levels of, full-
length SMN in the SMN complex and provides insight into
the mechanism involving functional complex formation.
 
Results
 
Generation of transgenic mice and 
genotype–phenotype analysis
 
We previously identified three unrelated SMA patients
(two with type III SMA and one with type II SMA) carry-
 
ing a single 
 
SMN2
 
 allele and an SMN A2G missense muta-
tion (Parsons et al., 1998). A cDNA carrying the A2G mu-
tation under a 3.4-kb SMN promoter fragment (Monani et
al., 1999b) (Fig. 1 A) was microinjected into fertilized
mouse oocytes. Of the four founders obtained, the two
transmitting lines, 2002 and 2023, were first analyzed for
transgene copy number and then mated to low copy
 
SMN2;Smn
 
 
 
/
 
 
 
 mice (Monani et al., 2000). To assess the
number of copies of the SMN A2G allele in each of the
lines, Southern blot analysis of tail DNA using probes that
bound SMN A2G and murine 
 
Smn
 
, respectively, was per-
formed. Relative to the single copy murine 
 
Smn
 
 gene, line
2002 was found to have 15 copies of the transgene whereas
line 2023 carried 11 copies (Fig. 1 B). Double transgenic
 
SMN A2G;SMN2;Smn
 
 
 
/
 
 
 
 mice were interbred or crossed
to 
 
SMN2;Smn
 
 
 
/
 
 
 
 
 
animals, resulting in mice carrying one
or two copies of 
 
SMN2
 
 and the mutant transgene but com-
pletely lacking mouse 
 
Smn (SMN A2G;SMN2;Smn
 
 
 
/
 
 
 
)
 
(Fig. 1 C). Mice of this genotype from line 2002 were no
different from the severe type I SMA mice we have previ-
ously described. On Western blot analysis, this line was
found not to express the A2G transgene (unpublished
data), possibly due to a site-specific integration effect.
However, 
 
SMN2;Smn
 
 
 
/
 
 
 
 mice carrying the A2G transgene
from line 2023 display all of the characteristics of type III
SMA. 
 
Smn
 
 
 
/
 
 
 
 animals with a single copy of 
 
SMN2
 
 and
heterozygous for the A2G transgene are 20–40% smaller
(1.14 
 
 
 
 0.06; 
 
n
 
 
 
 
 
 5) than their normal littermates
(1.62 
 
 
 
 0.18; 
 
n
 
 
 
 
 
 11) at birth and continue to remain so
during development and into adulthood (Fig. 1, D and F).
At 3 wk of age, these mice are less active than normal sibs.
In addition, they begin to display signs of muscle weakness,
as evidenced by a tendency to clasp the hind limbs when
suspended by the tail (Fig. 1 E). 
 
SMN2;Smn
 
 
 
/
 
 
 
 mice that
are homozygous for the A2G transgene have a considerably
milder phenotype and are indistinguishable from normal
littermates often into adulthood. This is consistent with
previous reports indicating a tight correlation between
 
SMN2
 
 copy number/protein levels and disease severity
(Lefebvre et al., 1997; Coovert et al., 1997). Both heterozy-
gous and homozygous A2G 
 
SMN2;Smn
 
 
 
/
 
 
 
 mice breed, al-
though the former are less efficient and live 
 
 
 
1 yr. Mean
survival of heterozygous A2G 
 
SMN2;Smn
 
 
 
/
 
 
 
 mice is 227 d
(
 
n
 
 
 
 
 
 14) versus 5.16 d for type I SMA mice (
 
n
 
 
 
 
 
 57) and
736 d for Smn
 
 
 
/
 
 
 
 mice (
 
n
 
 
 
 
 
 12) (see Fig. S1, available
online at http://www.jcb.org/cgi/content/full/jcb.200208079/
DC1). Toward the end of their lives, type III SMA mice
heterozygous for the A2G transgene exhibit very little ac-
tivity, short, shallow breathing, lose considerable weight,
and fail to groom efficiently. In contrast, the oldest 
 
SMN2;
Smn
 
 
 
/
 
 
 
 mice homozygous for the A2G transgene are cur-
rently 15 mo of age, healthy, and the males continue to
breed well.
To determine whether the mutant A2G transgene is capa-
ble of rescuing 
 
Smn
 
 
 
/
 
 
 
 embryonic lethality on its own, 
 
SMN
A2G;Smn
 
 
 
/
 
 
 
 intercrosses were set up. Out of 102 progeny
mice genotyped, none were found to be 
 
Smn
 
 
 
/
 
 
 
.
 
 This sug-
gests that the A2G mutant transgene is unable to rescue em-
bryonic lethality. To determine when embryonic lethality
occurs in 
 
SMN A2G;Smn
 
 
 
/
 
 
 
 mice, E12 embryos (
 
n
 
 
 
 
 
 60)T
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from 
 
SMN A2G;Smn
 
 
 
/
 
 
 
 
 
intercrosses were genotyped. None
were found to be 
 
Smn
 
 
 
/
 
 
 
, indicating that death occurs be-
fore this stage in development. This is similar to 
 
Smn
 
 
 
/
 
 
 
and 
 
Smn
 
 7/ 7 mice, which also die early in embryogenesis
(Schrank et al., 1997; Hsieh-Li et al., 2000).
Decreased self-association 
of mutant A2G SMN molecules
SMN self-associates using domains encoded by exons 2b and
6 (Lorson et al., 1998; Young et al., 2001). We investigated
the effect of the missense A2G mutation on self-association.
A GST–SMN A2G fusion protein was immobilized on glu-
tathione-linked agarose beads and then incubated with 
35S-
labeled SMN A2G protein. Bound fractions were washed
extensively and resolved by SDS-PAGE. As controls, simi-
lar self-association studies were performed with full-length
SMN and  7 SMN. Our results show that SMN A2G mol-
ecules self-associate with an efficiency between that of full-
length SMN and  7 SMN (Fig. 2 A) as do other mild SMA
mutations (Lorson et al., 1998). This is consistent with the
mild SMA phenotype we see in patients carrying this muta-
tion and our SMN A2G;SMN2;Smn
 /  mice. To determine
the effect of the A2G mutation on the ability of the mutant
protein to bind native full-length (FL) SMN and Sm pro-
teins, GST–SMN and GST–SmN fusion proteins immobi-
lized on agarose beads were incubated with labeled SMN
A2G. Bound fractions were washed as described above. As a
comparison, the ability of  7 SMN and FL-SMN each to
bind to SmN and native SMN was assessed. As expected,
SMN A2G binds FL-SMN with a higher affinity than does
 7 SMN but with a lower affinity than does native SMN
(Fig. 2 B). Interestingly, the ability of SMN A2G to bind the
Sm protein SmN was greatly decreased even though the mu-
tation does not lie in the Sm binding domain (Fig. 2 C).
Figure 1. Generation and 
characterization of mild SMA mice. 
(A) Schematic representation of the 
4.9-kb SMN A2G mutant transgene 
used to create transgenic mice. 
(B) Transgene copy number using 
Southern blot analysis. The blot was 
simultaneously probed with fragments 
that recognize the transgene and 
murine Smn, respectively. The latter, 
which is present in two copies per 
genome, serves as an internal control. 
Lane 1, DNA from a nontransgenic 
Smn
 /  animal; lane 2, line 2023; lane 
3, line 2002. (C) Southern blot analysis 
after BamHI digestion of tail DNA from 
mice from line 2023. Presence/absence 
of the wild-type murine Smn and Smn 
knockout (KO) allele was determined 
using a probe in murine Smn intron 1. 
Lane 1, type I SMA mouse control; lane 
2, Smn
 /  normal mouse; lane 3, SMN 
A2G;SMN2;Smn
 /  female mouse; 
lane 4, SMN2;Smn
 /  male lacking the 
A2G transgene; lanes 5 and 6, type III 
SMA pups of mice from lanes 3 and 4. 
Note that after genotyping for murine 
wild-type Smn and the KO alleles, the 
blot was stripped and reprobed to 
check for the presence of the A2G 
transgene. Genotyping for SMN2 was 
done by PCR (not depicted). 1-mo-old 
type III SMA mouse and a normal 
littermate showing a difference in size 
(D) and muscle weakness (E), as 
displayed by a hindlimb clasping reflex 
(arrow) in the former. Four of four type 
III SMA animals heterozygous for the 
A2G transgene displayed this reflex, 
compared with one out of four type III 
SMA animals homozygous for the 
mutant transgene and one of five normal 
littermates. (F) Weight curves of mild 
SMA mice (n   5) heterozygous for the 
A2G transgene and SMN2 and normal 
littermates (n   5). Error bars indicate 
standard deviation. An asterisk indicates that there was a significant difference (P   0.05, t test) in weights measured on the given days. As 
adults (33 d of age), mild SMA mice were significantly smaller (14.16   0.52 g; n   5) than normal littermates (18.02   1.08 g; n   5).T
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Expression of the mutant SMN A2G transgene
To assess the expression of the SMN A2G transgene, RT-
PCR studies (Fig. 3 A) on A2G animals lacking SMN2 and
Western blot analyses on mild SMA animals (Figs. 3, B and
C) were performed. Our data show that the transgene is ex-
pressed in all of the tissues examined. This is similar to the
expression of the endogenous gene, suggesting that the 3.4-
kb promoter fragment used here contains the necessary ele-
ments for ubiquitous expression. Western blot analysis per-
formed on SMN A2G;SMN2;Smn
 /  animals shows that
mild SMA mice express significantly higher SMN levels
than do age-matched type I SMA mice, but not as much as
normal littermates (Fig. 3 B). Furthermore, type III SMA
animals homozygous for the A2G transgene express higher
levels of the SMN protein than do heterozygous animals
(Fig. 3 C). This is consistent with previous data showing
that a tight correlation exists between SMN levels and phe-
notypic severity in SMA.
Figure 2. In vitro binding studies on SMN A2G. (A) Self-association studies between 
35S-labeled SMN proteins and bound GST–SMN fusion 
proteins. (B) The interaction of SMN A2G, FL-SMN, and  7 SMN each with FL-SMN. (C) Binding of FL-SMN, SMN A2G, or  7 SMN (as indicated) 
with the Sm protein SmN. In all three studies, binding values were calculated as a % of 
35S-labeled SMN A2G, FL-SMN, or  7 SMN.
Figure 3. Expression analysis of the mutant SMN 
A2G transgene in transgenic mice. (A) RT-PCR on 
RNA from indicated tissues of an SMN A2G;Smn
 /  
animal was performed as described in the Materials 
and methods. The  -actin gene was simultaneously 
amplified as a control. (B) Western blot analysis on 
5-d-old type I SMA, type III SMA, and an Smn
 /  
mouse was performed using the anti-SMN 
monoclonal antibody, MANSMA2. The blot was 
subsequently stripped and probed with an 
anti– -actin antibody to control for loading 
amounts. Type I SMA mice produce very little 
SMN, which is visible only after longer exposures. 
(C) Western blot analysis on 3.5-mo-old type III 
SMA mice (heterozygous for the A2G transgene, 
Het.), type III SMA mice (homozygous for the A2G 
transgene, Hom.), and normal mice (Smn
 / ) using 
the anti-SMN monoclonal antibody, MANSMA2. 
 -actin or  -tubulin serve as loading controls.T
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Type III SMA mice exhibit muscle atrophy and partial 
restoration of gems in the spinal motor neurons
One of the most striking features of spinal muscular atrophy
is the loss of the anterior horn cells (  motor neurons) of the
spinal cord and a greatly reduced amount of SMN in these
cells. We have previously shown that there is little or no
staining of SMN in the motor neurons of type I SMA mice
(Monani et al., 2000). To ascertain whether type III SMA
mice express SMN in their spinal motor neurons, spinal cord
sections from the lumbar and thoracic regions of 1-mo-old type
III SMA mice, with a single copy of SMN2 and heterozy-
gous for the A2G transgene, and age-matched Smn
 /  con-
trols were immunocytochemically stained (Fig. 4, A and B).
Based on the cytoplasmic staining and presence of gems in
the spinal cord of diseased animals, it is clear that SMN is re-
stored in motor neurons (Fig. 4 A). To quantitate the num-
ber of gems in the motor neurons of normal (n   2) and
type III SMA mice (n   3), 10 different fields, under 600 
magnification, from spinal cord sections of each mouse were
selected and the gems counted. An average of 4.5 nuclear
gems were counted per field ( 60 nuclei) in type III SMA
mice versus 9.8 nuclear gems in the age-matched controls.
Thus it is clear that although SMN is easily detected in the
spinal motor neurons of type III SMA mice, it is only a par-
tial restoration.
A second characteristic feature of SMA is muscular atrophy
due to denervation. We examined the gastrocnemius, quadri-
ceps, and intercostal muscles of type III SMA mice from the
above study to look for atrophy. Transverse sections of the
gastrocnemius muscle showed numerous angulated and atro-
phic fibers (Fig. 4 C) compared with uniform-sized fibers in
the age-matched controls (Fig. 4 D). This was less pro-
nounced in the quadriceps and intercostal muscles of these
animals (unpublished data), but is consistent with findings in
some human type III SMA patients (Dubowitz, 1995).
Electrophysiological studies and evidence of axonal 
sprouting in type III SMA mice
To further characterize the muscle weakness in our type III
SMA mice, EMG recordings were made on 4–6-mo-old
SMN2;Smn
 /  animals heterozygous for the mutant SMN
A2G transgene. Recordings were made on resting muscle as
it is difficult to obtain controlled, voluntary muscle contrac-
tion in mice. Normal muscle is electrically silent at rest and
no spontaneous activity is detected after cessation of move-
ment of the recording needle. In both of the type III (1SMN
A2G;SMN2;Smn
 / ) animals we tested, we found abnormal
spontaneous activity of single muscle fibers (fibrillation po-
tentials) and of motor units (fasciculation potentials) accom-
panied occasionally by biphasic positive sharp waves (Fig. 5,
A and B). These observations made on multiple pelvic (cra-
nial tibial, vastus lateralis, and gastrocnemius; see Fig.
S2, available online at http://www.jcb.org/cgi/content/full/
jcb.200208079/DC1) and thoracic (suprascapular) muscles
are a clear indication of denervation and provide a simple di-
agnosis of this process, as previously demonstrated in human
patients (Dubowitz, 1995). We did not see abnormal electri-
cal activity in age-matched type III SMA animals homozy-
gous for the A2G transgene, indicating that increased levels
of SMN from the A2G transgene correct this abnormality.
Figure 4. Immunocytochemical staining 
of spinal cord, and hematoxylin and 
eosin staining of muscle. Staining of 
SMN in spinal cord sections of 
(A) 1-mo-old SMN A2G;SMN2;Smn
 /  
type III SMA mouse and (B) an age-
matched Smn
 / control. Type III SMA 
mice express SMN in the motor neurons 
(arrows). However, nuclear gems in 
these animals are less intense and not 
as numerous as those seen in normal 
littermates. (600  magnification). 
Gastrocnemius from the same animals 
was sectioned and stained with 
hematoxylin and eosin. Numerous 
angulated and atrophied fibers (arrows) 
are evident in (C) type III SMA muscle as 
compared with (D) normal muscle 
(200  magnification). T
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This is consistent with data from some very mildly affected
type III SMA patients (Hausmanowa-Petrusewicz and Kar-
wanska, 1986). To assess the nature of the muscle weakness
in mild SMA mice, we analyzed evoked compound action
potentials and motor nerve conduction velocities (MNCVs)
of the tibial nerve (Fig. 5 C). Although nerve conduction ve-
locity tests on type III SMA (30.1   5.6; n   4) mice did
not show a significant difference from those on age-matched
controls (31.6   3.3; n   4), the amplitudes of the evoked
muscle potentials were reduced (SMA, 4.3   5.5, n   4;
normals, 15.07   8.9, n   4). These results indicate that
demyelination of nerves is not a feature of SMA. Instead, it
is likely that defects in neuronal axons contribute to SMA
pathology in mildly affected mice.
To compensate for chronic denervation in motor neuron
diseases, the surviving axons often sprout and reinnervate
the denervated fibers. In rat soleus muscle, cross innerva-
tion by a foreign nerve at a site distant from the original
end plate often preserves the old end plate. The original
end plate may persist as long as 4 mo after the fiber has lost
its nerve connection (Frank et al., 1976). We observed an
increased number of neuromuscular junctions in the gas-
trocnemius of type III SMA mice (90; n   3) compared
with age-matched controls (51; n    3). To investigate
whether axonal sprouting might account for this, 50- m
sections of freshly frozen gastrocnemius, triceps, and inter-
costal muscle were dual stained for axons and acetylcho-
line-esterase activity. We show that sprouting does indeed
occur both in type III SMA mice (n   3) heterozygous for
the A2G transgene as well as type III SMA mice homozy-
gous for the A2G transgene (Fig. 5, D–G). Sprouts were
nodal and were also seen to emerge from the neuromuscu-
lar junction (terminal sprouts). This was not observed in
Smn
 /  (n   2) or eight-copy SMN2;Smn
 /  mice (unpub-
lished data) and is consistent with data from mild SMA pa-
tients (Vogt and Nix, 1997). To determine the extent of
sprouting, synapses in the gastrocnemius and triceps mus-
cles from mild SMA mice heterozygous for the A2G trans-
gene (n   3) and Smn
 /  littermates (n   2) were scored
for the presence or absence of sprouts. Our data show that
there is a significant increase in the number of sprouts in
both gastrocnemius (SMA, 22   4%; normal, 7   2.5%)
and triceps (SMA, 21   3%; normal, 7.2   3%) muscles
of mild SMA mice (Fig. 5 G).
Figure 5. Electromyography and axonal sprouting 
in mild SMN mice. EMG recordings in (A) cranial 
tibial and (B) suprascapular muscle of 4-mo-old 
type III SMA mice. Spontaneous abnormal electrical 
activity was recorded in the form of fibrillation 
potentials (dark arrows) and occasional biphasic 
positive sharp waves (red arrow). (C) Quantification 
of MNCVs and the amplitudes of compound muscle 
action potentials in type III SMA mice and normal 
(Smn
 / ) littermates. At least four mice from each 
group were analyzed. Data are given as mean   SD. 
Although the amplitude was reduced in SMA mice 
(P   0.05, t test), the MNCVs did not significantly 
change. Axonal sprouting in the (D) gastrocnemius 
and (E) triceps of type III SMA mice is a further sign 
of denervation. The former is an example of nodal 
sprouting whereas the latter depicts terminal 
sprouts (red arrows). Arrow in white indicates main 
axonal branch. Motor axons are silver stained in 
black while neuromuscular junctions stain blue. 
Normal gastrocnemius (F) shows at least three 
different motor axons, each innervating a separate 
muscle fiber (running diagonally from lower left to 
upper right; magnification 400 ). Graphical 
representation (G) of the extent of sprouting (terminal 
and nodal) in type III SMA mice and unaffected 
littermates. Data are given as mean   SD.T
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Motor neuron degeneration in type III SMA mice
To assess motor neuron degeneration in 3.5-mo-old SMN2;
Smn
 /  type III SMA mice heterozygous for the A2G trans-
gene, transverse sections of the spinal lumbar region (unpub-
lished data) and coronal sections of the facial nucleus (Fig. 6,
A and B) were stained with cresyl echt violet and the mor-
phology and numbers of the cells determined. The most ob-
vious difference between the SMA mice and age-matched
controls is a significant decrease in the numbers of motor
neurons in the former. In the lumbar spinal cord, SMA mice
have 29% fewer motor neurons than age-matched Smn
 / 
controls, while in the facial nucleus there is a  19% loss of
motor neurons (Table I; Fig. 6, A and B). Previously, we
showed a significant loss of motor neurons in the spinal cord
and brain stem of 5-d-old severe SMA mice (Monani et al.,
2000). To determine whether motor neuron loss occurs this
early in type III SMA mice, 5-d-old SMN2;Smn
 /  animals
heterozygous for the A2G transgene were killed and motor
neuron cell bodies in the facial nucleus counted. We found
no evidence of motor neuron loss at this age in type III SMA
mice (unpublished data). This is consistent with our previ-
ous finding that motor neuron loss is a late event in SMA.
To further examine motor neuron degeneration, we also
conducted ventral root counts on our type III SMA mice.
Mice perfused with 4% paraformaldehyde, 1% glutaralde-
hyde were used to isolate the ventral roots from the L1–L5
lumbar spinal cord region. Semi-thin sections were cut,
stained with toluidene blue (Fig. 6, C and D), and at least
four different fields examined to quantitatively determine
the number of motor axons in the roots of diseased mice and
an age-matched control. Two striking differences were ob-
served. First, type III SMA mice have fewer myelinated ax-
ons (Table II). The loss in motor axons correlates with the
loss of motor neuron cell bodies in the spinal cord. Second,
many of the remaining axons in the diseased mice are shriv-
eled and exhibit signs of Wallerian degeneration (Fig. 6 D).
Discussion
Mice lacking murine Smn but carrying one to two copies of
human SMN2 provide a suitable animal model of type I spi-
nal muscular atrophy (Hsieh-Li et al., 2000; Monani et al.,
2000). In this study, we have introduced a transgene carrying
a missense mutation in exon 1 of the SMN gene into the se-
vere SMA genetic background. SMN2;Smn
 /  mice that are
heterozygous for the mutant transgene exhibit many of the
clinical and pathological characteristics of type III (mild)
SMA. These mice suffer from motor neuron degeneration
and its associated effects. They include evidence of motor
axon degeneration, loss and sprouting, muscle atrophy, and
abnormal EMG patterns. Other obvious clinical features of
SMA in our mice include muscle weakness, reduced activity,
and a decreased life span. In keeping with numerous previous
studies showing a tight correlation between levels of SMN2
copy number/SMN protein and disease severity, SMN2;
Smn
 /  mice homozygous for the mutant transgene exhibit a
very mild disease phenotype. Indeed, there are few overt
signs of muscle weakness in 6-mo-old animals and a rela-
tively prolonged lifespan ( 15 mo) compared with heterozy-
gous SMN A2G transgenic mice. We have previously shown
that type I SMA mice lose 35–40% of their motor neurons
by the time they die, while Jablonka et al. (2000) showed up
to 50% spinal motor neuron loss in 12-mo-old Smn
 /  ani-
mals. Yet type I SMA mice rarely live beyond 6 d of age,
whereas Smn
 /  animals live completely normal lives and ex-
hibit no clinical signs of SMA. The implications are, first,
that a 50% motor neuron loss is completely compatible with
life and, second, that the surviving motor neurons in type I
SMA mice are too sick to function normally thus resulting in
early death. Motor neuron loss in type III SMA mice occurs
significantly earlier than in Smn
 /  heterozygotes but not as
early as in type I SMA mice. The widely varying phenotypes
but similar numbers of motor neurons lost in severe, mild,
and Smn
 /  mice imply that the timing of cell loss, rather
than the actual numbers lost, is important. Disease symp-
toms in type III SMA mice, as evidenced by muscle weak-
ness, occur as early as 1 mo of age. If, as we suspect, onset of
the disease correlates with motor neuron dysfunction, we
would expect to see electrophysiological abnormalities at this
age. Interestingly, recent similar studies involving motor unit
number estimation (MUNE) in pre- and post-symptomatic
human patients revealed that a large number of motor neu-
rons are present before the onset of the phenotype and that
there is a rapid decline in the numbers of motor units with
disease progression (Bromberg and Swoboda, 2002). This is
similar to studies involving morphometric counts in severe
SMA mice, which show a correlation between motor neuron
loss and onset of disease symptoms. As EMG studies can be
performed on mild SMA mice, it will be possible to correlate
motor neuron counts with MUNE/EMG studies in order to
determine if neuronal loss in SMA occurs as a dying back
process, as has been found in another mouse model of motor
neuron disease (Holtmann et al., 1999).
It is intriguing to consider how the A2G mutation on an
SMN2;Smn
 /  background results in a mild SMA pheno-
type. The mutation is the most 5  one reported so far. It is
neither in the oligomerization domain in exon 6 nor in exon
Table I. Number of facial and spinal motor neurons in the brain stem and lumbar (L1–L6) spinal cord, respectively, of 3.5-mo-old SMN2;
Smn
 /  type III SMA mice heterozygous for the A2G transgene and age-matched controls
Type of motor neurons Type III SMA Normal Reduction
Facial nucleus 2,994   94 (n   4) 3,695   171 (n   2)  19% (P   0.05)
Spinal motor neurons 3,144   201 (n   4) 4,421   76 (n   2)  29% (P   0.05)
Table II. Number of motor axons in the lumbar ventral roots of 
type III SMA mice and normals
Age (mo) Type III SMA Normal Reduction
5 599   61 (n   4) 801   90 (n   5)  25% (P   0.05)T
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2b. It is not in the Sm protein binding domain nor does it
affect SIP-1 binding (unpublished data). Yet, we have shown
that the A2G mutation does disrupt self-association and af-
fects SmN binding presumably by disrupting the formation
of SMN oligomers. A to G mutations have been shown to
profoundly affect  -helices (Lyu et al., 1990; Chakrabartty
et al., 1991). It is not unlikely that the mutation disrupts the
three-dimensional structure of the protein enough to affect
Figure 6. Motor neuron cell bodies and ventral roots in mild SMA mice. Motor neuron degeneration in the (A) facial nucleus and (C) lumbar 
spinal cord of a 3.5-mo-old type III SMA mouse showing fewer cells with intact nuclei compared with the normal Smn
 /  control in B and D, 
respectively. An examination of the motor axons in the ventral roots of (E) type III SMA mice by toluidine blue staining shows a myelin ovoid 
and numerous axons undergoing Wallerian degeneration (arrows). F represents an age-matched normal control (magnification 600 ).T
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the oligomerization domains in exon 2b and/or exon 6 as
well as the Sm binding domain. Although the A2G protein
retains some level of self-association activity, it is possible
this deficiency results in that mutant’s inability to form
higher order complexes necessary for SMN function and in-
teractions with protein partners. This could explain why
SMN A2G does not rescue Smn
 /  embryonic lethality. If,
however, full-length SMN serves as a scaffold, then low lev-
els of the protein might promote the formation of higher or-
der FL-SMN:SMN A2G oligomers with an enhanced ability
to bind other interacting proteins such as SmN. Our data
show that SMN A2G binds with a higher affinity to FL-
SMN than does  7 SMN. FL-SMN:SMN A2G complexes
would therefore be more stable than FL-SMN: 7 SMN
ones. Furthermore, it has been shown that protein levels in
patients with missense mutations correlate with the disease
phenotype (Lefebvre et al., 1997). These data and our obser-
vations lead us to a plausible molecular model of SMA (Fig.
7) in which SMN forms a number of complexes with differ-
ent partners. These partners compete for the same sites on
SMN, binding being determined by their relative affinities
for SMN. In the presence of low levels of full-length SMN,
low affinity binding partners are out-competed by high af-
finity proteins. It is possible that the low affinity binding
partners are selectively found in motor neurons and are un-
able to form functional complexes in SMA patients due to
the low SMN levels. Loss or disruption of the low affinity
complex in motor neurons would result in the degeneration
of these, but not other, tissues. Our model is consistent with
the observation of increased SMN levels and a mild pheno-
type in mice carrying the A2G missense mutation on a se-
vere SMA genetic background.
Despite recent advances in elucidating the functions of
SMN, including studies implicating SMN to be important
in neural growth cones and in RNA editing/transport in mo-
tor axons (Fan and Simard, 2002; Rossol et al., 2002), the
selective loss of   motor neurons in SMA remains far from
clear. The functions attributed to SMN would seem to be
important in all cells, yet it is the motor neuron that is most
profoundly affected. The presence of a low affinity SMN in-
teracting partner in these but not other cells may explain the
specificity of the disease. A majority of the mutations in
SMA affect either oligomerization, binding of one of SMN’s
interacting partners, or both. This has been assessed either in
vitro or in cell culture but not in motor neurons. It is unclear
whether the same function(s) is disrupted in these cells in a
diseased animal. Our type III SMA mice may allow us to ad-
dress this by providing us with the ability to create motor
neuron cell lines and study the effect of the A2G missense
mutation on the SMN macromolecular complex. What is
clear is that the A2G missense mutation is unable to rescue
embryonic lethality in Smn
 /  mice. Because this is a mild
mutation, we would expect severe missense mutations to
have the same effect. This is in contrast to a study by Wang
and Dreyfuss (2001) in which they report the ability of a
number of missense mutations to rescue lethality in a
chicken cell line. Two ways of explaining our discordant re-
sults are, first, leaky expression of very low levels of full-
Figure 7. A molecular model of SMA that may explain the motor neuron specificity of the disease. A protein with a low affinity for SMN 
expressed selectively in the motor neurons would be unable to bind and form a functional complex in these cells in an SMA patient. This 
would result in degeneration and loss of motor neurons but not other tissues.T
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length SMN in the chicken cell line, and, second, a critical
requirement for intact SMN during development in a whole
animal, but not in a cell line, which is disrupted in its ab-
sence, leading to embryonic lethality. A number of groups
have reported compounds capable of increasing SMN from
SMN2. It will be important to assess these in an appropriate
animal model of SMA. The mild SMA mouse we have gen-
erated here has certain distinct advantages over previously re-
ported animal models. It has a clear and consistent SMA
phenotype but is more robust than severe SMA mice and
therefore amenable to drug administration protocols. We
have shown that denervation in mild SMA mice may be
measured electrophysiologically. Additionally, the abnormal
EMGs indicative of denervation correlate with SMN protein
levels. Standard EMG analysis could be complemented with
MUNE studies, which would serve to further refine ways of
measuring the outcome of any drug treatment studies. It is
therefore clear that our mice are an important tool in (a) en-
suring the safety and efficacy of drugs/molecules that we and
others are currently isolating in high-throughput screens and
(2) the evaluation of gene therapy procedures for SMA.
Materials and methods
Generation of transgenic mice and breeding strategy
A forward primer, 5 -GCAGGATCCTATGGGGATGAGCAGCGG-3 , in
SMN exon 1 containing an engineered BamHI site and the C to G transi-
tion, which results in the A2G mutation, and a reverse primer in exon 8,
5 -CCGAATTCAGTACAATGAACAGCCATGTCCACC-3 , containing an
EcoRI site were used to amplify SMN by RT-PCR. The  1.5-kb product
was digested with BamHI and EcoRI and cloned into the pcDNA3 (Invitro-
gen) vector. Separately, a  3.4-kb KpnI–SacII SMN promoter fragment was
cloned into the pEGFP (CLONTECH Laboratories, Inc.) vector and then ex-
cised out using KpnI and BamHI. This fragment was directionally ligated to
the SMN cDNA in pcDNA3. The 4.9-kb promoter–SMN transgene was
then excised with KpnI and BamHI and injected into fertilized FVB mouse
oocytes. Potential founders were screened by Southern analysis using an
exon 6–8 SMN cDNA probe or by PCR using the following primers: 4.5F,
5 -ACTGGGACCAGGAAAGCCGGT-3 , and 6R, 5 -GCCAGTATGAT-
AGCCACTCATG-3 . Founders were bred to SMN2;Smn
 /  mice we have
previously generated. SMN A2G;SMN2;Smn
 /  animals were then either
interbred or backcrossed with SMN2;Smn
 /  mice, resulting in SMN A2G;
SMN2;Smn
 /  animals.
In vitro binding assays
SMN A2G, FL-SMN, and  7 SMN cDNAs were subcloned into the vector
pGEX-3X (Amersham Biosciences). GST fusion proteins were prepared and
purified using glutathione-linked agarose beads as previously described
(Lorson et al., 1998). To prepare 
35S-labeled SMN proteins, the T7 tran-
scription/translation (TnT) rabbit reticulocyte lysate system (Promega) was
used. The protocol was essentially the same as that described by Lorson et
al. (1998) except that densitometry was performed using a Phosphorimager
(Molecular Dynamics, Inc.)
RT-PCR, Southern, and Western analysis
To determine the expression of the mutant A2G transgene, Smn
 /  carry-
ing the transgene but no SMN2 were killed by cervical dislocation and
polyA
  RNA was isolated using the QuickPrep Micro mRNA purification
kit (Amersham Biosciences) according to the manufacturer’s recommenda-
tions. After treating the RNA with DNase I to get rid of contaminating ge-
nomic DNA,  100 ng was reverse transcribed and amplified using the
following human SMN-specific primers in exons 1 and 4, respectively:
Ex1F, 5 -GCGGCGGCAGTGGTGGCGGC-3 , and Ex4R, 5 -TGGAGCA-
GATTTGGGCTTGA-3 . Native murine Smn and the knockout allele were
followed by Southern blot analysis after Bam HI digestion of tail DNA us-
ing a probe in Smn intron 1. The probe was radioactively labeled and hy-
bridized to the filter containing the DNA according to standard methods.
The filter was washed at high stringency and then exposed to Hyperfilm
MP (Amersham Biosciences) with an intensifying screen. Copy number of
the SMN A2G transgene was determined by Southern blot analysis of DNA
from SMN A2G;Smn
 /  animals. An SMN exon 6–8 cDNA fragment and a
murine Smn intron 1 probe of approximately equal length and GC content
were radioactively labeled and simultaneously hybridized to the blot. The
blot was washed and exposed to film as described above. Intensities of
bands corresponding to the transgene were then determined using a Shi-
madzu 9000 CS scanner. Copy number was determined by comparing the
intensities of these bands to those of the single-copy murine Smn gene in
each animal. For Western blot analysis, 100 mg of tissue from 5-d-old
mice was dissolved in blending buffer (10% SDS, 62.5 mM Tris, pH 6.8, 5
mM EDTA). 25–50  g of protein was mixed with an equal volume of sam-
ple buffer (62.5 mM Tris, pH 6.8, 10% glycerol, 10% 2 ME, 0.4 mg bro-
mophenol blue) and electrophoresed on a 12.5% polyacrylamide gel.
Samples were transferred to Immobilon P (Millipore) as previously de-
scribed (Coovert et al., 1997). The blot was blocked in 5% milk powder,
0.5% BSA in TBS-Tween for 2 h, and then incubated for 1 h with anti-SMN
primary antibody (MANSMA2). Bound primary antibody was detected by
HRP-conjugated secondary antibody followed by chemiluminescence
(Amersham Biosciences). The blots were then stripped and reprobed with
a  -actin antibody to control for loading amounts.
Histology and immunocytochemistry
For hematoxylin-eosin stains and spinal cord immunocytochemistry, adult
type III SMA mice and normal controls were killed by CO2 gas, transcar-
dially perfused briefly with cold 1  PBS, and the muscle and spinal cord
tissue dissected out, mounted on wooden blocks, and flash frozen in liquid
nitrogen–cooled isopentane. 10–12- m thick transverse muscle sections
were cut, mounted on Superfrost (Fisher Scientific) slides, and then air
dried before processing. Sections were fixed in 100% alcohol (30 s), rinsed
in tap water, and stained in hematoxylin (Sigma-Aldrich) for 30 s followed
by a second rinse in tap water. They were then stained in eosin (Sigma-
Aldrich) for 20 s, rinsed in tap water, dehydrated in alcohol, and cleared in
xylene before mounting in Permount (Sigma-Aldrich) for light microscopy.
Immunocytochemistry on spinal cord sections was essentially performed
as described previously (Monani et al., 2000). For motor neuron studies
and ventral root counts, mice were transcardially perfused with 1  PBS
followed by 4% paraformaldehyde, 1% glutaraldehyde. Ventral roots,
lumbar spinal cord, and the brain stem were post-fixed for 24 h in the
same solution. The brain stem and spinal cord were then embedded in
paraffin according to conventional procedures. Serial sections (6  m) pre-
pared with a rotary microtome (American Optical Instruments) were
mounted on glass slides and Nissl’s stained as previously described (Sendt-
ner et al., 1990). Ventral roots were post-fixed in 1% osmium tetroxide
(1 h), rinsed in 0.1 M phosphate buffer (pH 7.3), and then dehydrated.
They were then embedded in Spurr resin and 0.5- m sections were cut on
a Reichert Ultracut E microtome. Sections were stained with toluidine blue
and visualized by light microscopy.
To look for axonal sprouting in type III SMA mice, animals were killed
by cervical dislocation and the intercostals, gastrocnemius, and triceps
muscles were dissected out. Muscle tissue was immersed in 3% disodium
EDTA for 20 s, mounted on wooden blocks, and flash frozen in liquid ni-
trogen–cooled isopentane. 50- m thick longitudanal sections were cut in
a cryostat and placed on Superfrost (Fisher Scientific) slides. A drop of 3%
disodium EDTA was immediately placed on the sections to prevent muscle
contracture and the sections were allowed to air dry. Cholinesterase and
axonal staining were performed as described previously (Pestronk and
Drachman, 1978), except that sections were stained in a 10% rather than
20% silver nitrate solution for 10 min. We found this reduces the extent of
muscle fiber shrinkage and separation and better preserves the integrity of
intramuscular nerves. To determine the extent of sprouting, synapses in ten
50- m thick sections from the gastrocnemius (medial and lateral parts) and
triceps were examined. The 500- m portion included the middle of the
muscle and sections on either side. Synapses were systematically scored
for those with or without sprouts. Terminal and nodal sprouts were com-
bined and expressed as a percentage of the total readable synapses. Ap-
proximately 400 synapses in each muscle were scored.
Electrophysiological studies
4–6-mo-old mice were anesthetized with an intraperitoneal injection of a
mixture of ketamine (60 mg/kg) and xylazine (3.5 mg/kg). They were main-
tained at 34 C under anesthesia using isofluorine. For EMG testing, a
monopolar needle (26 gauge; Electrode store) was used. Intramuscular po-
tentials were recorded on an EMG instrument (model Neuropack Four
mini [MEB-5304K]; Nihon Kohden Corp.). Muscle EMG testing was
grouped into the following sites: proximal thoracic limb muscles, proximal
pelvic limb muscles, distal thoracic limb muscles, distal pelvic limb mus-T
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cles, cervical epaxial muscles, and remaining epaxial muscles. The mini-
mum criteria used to define the presence of spontaneous activity was the
persistence of an abnormal waveform ( 3 s) after complete cessation of
needle movement that was reproducible with redirection of the EMG nee-
dle. MNCV recordings of the tibial nerve were performed with an Evoked
Potential Measuring System. Subdermal stimulating electrodes (10-mm
platinum safelead electrodes, model F-E2; Grass Instruments) were placed
at the sciatic notch (proximal stimulation site) and the head of the fibula
(distal stimulation site) for the sciatic nerve (upper tibial) evaluation. The
distal portion of the tibial nerve was evaluated by placing subdermal stim-
ulating electrodes at the head of the fibula (proximal stimulation site) and
the ankle (distal stimulation site). Percutaneous intramuscular recording
and reference electrodes (26 gauge, 40   0.45-mm monopolar needles;
Dantec Neurosupplies) were placed on the extensor digitorum brevis mus-
cle of the lateral toe. A ground subcutaneous electrode was placed over
the ankle. Stimulation was performed with a single square wave pulse of
0.2-ms duration at 1 Hz with a current of 10–15 mA. Reading parameters
for the M wave are an analysis time of 10 ms, sensitivity of 10 mV, and
band filter of 50–3,000 Hz. Motor nerve conduction was determined by
the formula Velocity (ms)   distance/time. Distance was measured using a
flexible tape between the cathodes of each stimulation site.
Online supplemental material
The supplemental material (Figs. S1 and S2) is available online at http://
www.jcb.org/cgi/content/full/jcb.200208079/DC1. Fig. S1 shows survival
curves for mild SMA mice, and Fig. S2 shows EMG results in the muscles
indicated.
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